Open for forecastingClinical TrialsReleased Dec 8, 2025

ACCESS (aleniglipron) Phase 2b obesity

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Program: ACCESS (Phase 2b) and exploratory ACCESS II (higher doses), randomized, double-blind, placebo-controlled. - Population: adults with obesity or overweight with comorbidity. - Duration: 36 weeks. - Key endpoints: mean percent change in body weight at Week 36 vs baseline; placebo-adjusted mean percent change; tolerability as discontinuation due to AEs.

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.